Spots Global Cancer Trial Database for A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
Official Title: A Phase II Study of Penpulimab Combined With Chemotherapy ± Anlotinib Hydrochloride in Patients With Advanced Nasopharyngeal Carcinoma
Study ID: NCT04736810
Conditions
Study Description
Brief Summary: This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Contact Details
Name: Xiaozhong Chen, MD
Affiliation: Cancer Hospital of The University of Chinese Academy of Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
